Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ApexOnco Front Page
Recent articles
And the company believes it won’t need to carry out another trial.
And that could affect the drug's third-line accelerated approval.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
A fresh licensing deal tidies up years of work between the two companies.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
